Get the Stockscreener App
9.31
0.53%
-0.05
After Hours:
9.25
-0.06
-0.64%
Foghorn Therapeutics Inc stock is traded at $9.31, with a volume of 94,953.
It is down -0.53% in the last 24 hours and up +12.44% over the past month.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
See More
Previous Close:
$9.36
Open:
$9.34
24h Volume:
94,953
Relative Volume:
0.63
Market Cap:
$515.11M
Revenue:
$34.16M
Net Income/Loss:
$-98.43M
P/E Ratio:
-3.3978
EPS:
-2.74
Net Cash Flow:
$-119.33M
1W Performance:
-0.11%
1M Performance:
+12.44%
6M Performance:
+38.75%
1Y Performance:
+86.20%
1-Day Range:
$9.17
$9.85
1-Week Range:
$9.15
$9.99
52-Week Range:
$2.70
$10.25
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Name
Foghorn Therapeutics Inc
Sector
Industry
Phone
617-586-3100
Address
500 TECHNOLOGY SQUARE, CAMBRIDGE
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-23 | Initiated | BofA Securities | Buy |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-22-21 | Initiated | H.C. Wainwright | Buy |
| Nov-17-20 | Initiated | Cowen | Outperform |
| Nov-17-20 | Initiated | Goldman | Buy |
| Nov-17-20 | Initiated | Morgan Stanley | Overweight |
| Nov-17-20 | Initiated | Wedbush | Outperform |
View All
Foghorn Therapeutics Inc Stock (FHTX) Latest News
Driehaus Capital Management LLC Grows Stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - MarketBeat
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock Holdings Increased by Rhumbline Advisers - Defense World
Deerfield Management Company L.P. Series C Purchases Shares of 2,518,500 Foghorn Therapeutics Inc. (NASDAQ:FHTX) - MarketBeat
Deerfield Management Company L.P. Series C Purchases Shares of 2,518,500 Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics exec sells over $360k in company stock By Investing.com - Investing.com South Africa
Foghorn Therapeutics exec sells over $360k in company stock By Investing.com - Investing.com Australia
Bank of New York Mellon Corp Buys 18,664 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
(FHTX) Long Term Investment Analysis - Stock Traders Daily
Foghorn Therapeutics exec sells over $360k in company stock By Investing.com - Investing.com Canada
Foghorn Therapeutics exec sells over $360k in company stock - Investing.com
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase - Benzinga
Foghorn Therapeutics (NASDAQ:FHTX) Price Target Raised to $9.00 - MarketBeat
Foghorn Therapeutics (NASDAQ:FHTX) PT Raised to $9.00 at Morgan Stanley - Defense World
Market Insight: Foghorn Therapeutics Inc (FHTX)’s Notable Gain, Closing at 9.99 - The Dwinnex
Foghorn Therapeutics exec sells over $116k in company stock By Investing.com - Investing.com Australia
Foghorn Therapeutics exec sells over $116k in company stock - Investing.com India
Foghorn Therapeutics exec sells over $116k in company stock - Investing.com
Foghorn Therapeutics exec sells over $116k in company stock By Investing.com - Investing.com UK
Foghorn Therapeutics exec sells over $116k in company stock By Investing.com - Investing.com South Africa
Foghorn Therapeutics executive sells over $107k in company stock By Investing.com - Investing.com Australia
Foghorn Therapeutics executive sells over $107k in company stock - Investing.com India
Foghorn Therapeutics executive sells over $107k in company stock - Investing.com
Foghorn Therapeutics executive sells over $107k in company stock By Investing.com - Investing.com UK
Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength? - MSN
Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength? - Yahoo Finance
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Sees Large Increase in Short Interest - MarketBeat
Foghorn Therapeutics (NASDAQ:FHTX) Sees Large Volume Increase - MarketBeat
Insider Sale: Chief Scientific Officer Steven Bellon Sells 20,000 Shares of Foghorn ... - Yahoo Finance
Insider Sale: Chief Scientific Officer Steven Bellon Sells 20,000 Shares of Foghorn ... By GuruFocus - Investing.com Canada
Insider Sale: Chief Scientific Officer Steven Bellon Sells 20,00 - GuruFocus.com
Foghorn Therapeutics (NASDAQ:FHTX) Reaches New 1-Year High at $9.22 - MarketBeat
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Sold by Panagora Asset Management Inc. - Defense World
Foghorn Therapeutics (NASDAQ:FHTX) Receives New Coverage from Analysts at Jefferies Financial Group - Defense World
Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 81.16%: Read This Before Placing a Bet - MSN
Foghorn Therapeutics appoints new Chief Business Officer - Investing.com
Wall Street Analysts Think Foghorn Therapeutics Could Surge 81.16%: Read This Before Placing a Bet - Benzinga
Foghorn Therapeutics (NASDAQ:FHTX) Receives New Coverage from Analysts at Jefferies Financial Group - MarketBeat
Foghorn Therapeutics Appoints Anna Rivkin, Ph.D. as Chief Business Officer - citybiz
Foghorn Therapeutics appoints Anna Rivkin as CBO - TipRanks
Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer - GlobeNewswire
Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer - Yahoo Finance
Jefferies bullish on Foghorn Therapeutics stock, cites cancer treatment advance - Investing.com UK
Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 81.16%: Read This Before Placing a Bet - Yahoo Finance
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares Climb 35% But Its Business Is Yet to Catch Up - Simply Wall St
(FHTX) On The My Stocks Page - Stock Traders Daily
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September - GlobeNewswire
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September - StockTitan
Raymond James & Associates Purchases 107,967 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Raymond James & Associates Acquires 107,967 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - MarketBeat
Foghorn Therapeutics (NASDAQ:FHTX) vs. Intellipharmaceutics International (OTCMKTS:IPCIF) Financial Review - Defense World
Foghorn Therapeutics (NASDAQ:FHTX) Coverage Initiated at Evercore ISI - MarketBeat
Foghorn Therapeutics Inc Stock (FHTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):